4.3 Article

Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw

Journal

CURRENT MEDICAL RESEARCH AND OPINION
Volume 32, Issue 7, Pages 1261-1268

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1185/03007995.2016.1170005

Keywords

Adverse event; Cooperation; Discontinuation; Jaw; Osteonecrosis; Osteoporosis

Funding

  1. Japan Society for the Promotion of Science [24592849, 26463148, 90119222]
  2. Grants-in-Aid for Scientific Research [15K11092, 24592849, 26463148] Funding Source: KAKEN

Ask authors/readers for more resources

Objective: Our previous questionnaire-based survey suggested that discontinuation of antiresorptive agents before tooth extraction may increase adverse events and disturb osteoporosis treatment without completely preventing osteonecrosis of the jaw (O.N.J.). We also found little cooperation between physicians and dentists in Japan. However, limitations of our previous study included a survey of doctors belonging to small clinics and a small sample size. Our current study aimed to confirm the results of our previous survey in doctors mainly belonging to academia. Methods: A structured questionnaire including 14 key clinical queries was sent to 1812 physicians of the Japan Osteoporosis Society, and 629 responses were received. Results: Dentists requested discontinuation of many medications that were not associated with the incidence of O.N.J. A total of 523 respondents had received discontinuation requests from dentists. Of these, 97 respondents experienced 119 adverse events including 25 fractures and seven incidences of O.N.J. The ratios of valid responses for fractures were 3.6% and 5.3% in patients with a discontinuation of < 3 and >= 3 months, respectively. Those for O.N.J. were 0.7% and 1.6%, respectively. Respondents who refused discontinuation requests reported no cases of O.N.J. Approximately 17% of respondents had patients who discontinued osteoporosis treatment following a requested drug discontinuation after tooth extraction. Approximately 62% of respondents did not request oral health care by a dentist before antiresorptive therapy, and 72% reported no cooperation between physicians and dentists in their region. Conclusions: This study reconfirms the results of our previous survey. Discontinuation of antiresorptive treatment may increase both fractures and O.N.J. Immediate development of a strategy for sharing information about O.N.J. among physicians, dentists, and patients is required to reduce the incidence of both O.N.J. and skeletal events in osteoporosis treatment. Study limitations were selection bias due to low response rate and possible inaccurate responses to the questionnaire.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Endocrinology & Metabolism

Efficacy on the risk of vertebral fracture with administration of once-weekly 17.5 mg risedronate in Japanese patients of established osteoporosis with prevalent vertebral fractures: a 156-week longitudinal observational study in daily practice

Satoshi Soen, Takashi Umemura, Tsuyoshi Ando, Toshiaki Kamisaki, Masahiko Nishikawa, Ryoichi Muraoka, Yoshinori Ikeda, Kyoko Takeda, Mitsuharu Osawa, Toshitaka Nakamura

JOURNAL OF BONE AND MINERAL METABOLISM (2017)

Article Endocrinology & Metabolism

Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw

Toshiyuki Yoneda, Hiroshi Hagino, Toshitsugu Sugimoto, Hiroaki Ohta, Shunji Takahashi, Satoshi Soen, Akira Taguchi, Toshihiko Nagata, Masahiro Urade, Takahiko Shibahara, Satoru Toyosawa

JOURNAL OF BONE AND MINERAL METABOLISM (2017)

Article Gastroenterology & Hepatology

Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study

Yuji Mizokami, Kazunori Oda, Nobuo Funao, Akira Nishimura, Satoshi Soen, Takashi Kawai, Kiyoshi Ashida, Kentaro Sugano

Article Endocrinology & Metabolism

Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

Bente L. Langdahl, Stuart Silverman, Saeko Fujiwara, Ken Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon P. Disch, Fernando Marin, John H. Krege

Article Endocrinology & Metabolism

Changes in quality of life in patients with postmenopausal osteoporosis receiving weekly bisphosphonate treatment: a 2-year multicenter study in Japan

Hiroshi Hagino, Satoshi Soen, Toshitsugu Sugimoto, Naoto Endo, Ryo Okazaki, Kiyoshi Tanaka, Toshitaka Nakamura

JOURNAL OF BONE AND MINERAL METABOLISM (2019)

Article Endocrinology & Metabolism

Study design of multi-center, open-label randomized controlled, head-to-head trial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04

Yukari Uemura, Shiro Tanaka, Teruhiko Miyazaki, Mayumi Tsukiyama, Teruki Sone, Akira Taguchi, Satoshi Soen, Satoshi Mori, Hiroshi Hagino, Toshitsugu Sugimoto, Masao Fukunaga, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Masataka Shiraki

JOURNAL OF BONE AND MINERAL METABOLISM (2019)

Article Endocrinology & Metabolism

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

Stuart Silverman, Bente L. Langdahl, Saeko Fujiwara, Ken Saag, Nicola Napoli, Satoshi Soen, Hiroyuki Enomoto, Thomas E. Melby, Damon P. Disch, Fernando Marin, John H. Krege

CALCIFIED TISSUE INTERNATIONAL (2019)

Article Endocrinology & Metabolism

Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid

Akira Taguchi, Yukari Uemura, Takumi Imai, Shiro Tanaka, Hiroaki Ohta, Toshitaka Nakamura, Hajime Orimo, Toshitsugu Sugimoto, Satoshi Soen, Masataka Shiraki

JOURNAL OF BONE AND MINERAL METABOLISM (2019)

Article Rheumatology

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi, Yoshiya Tanaka, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, Takaya Nitta, Naoki Okubo, Harry K. Genant, Desiree van der Heijde

ANNALS OF THE RHEUMATIC DISEASES (2019)

Article Endocrinology & Metabolism

Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis

Satoshi Soen, Hideaki Kishimoto, Hiroshi Hagino, Teruki Sone, Hiroaki Ohishi, Tsukasa Fujimoto, Emma Sasaki, Sakae Tanaka, Toshitsugu Sugimoto

JOURNAL OF BONE AND MINERAL METABOLISM (2020)

Article Endocrinology & Metabolism

Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study

Satoshi Soen, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Masako Ito, Tetsuo Nakano, Hiroshi Hagino, Akihiro Hirakawa, Toshio Matsumoto

JOURNAL OF BONE AND MINERAL METABOLISM (2020)

Article Endocrinology & Metabolism

Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients (e-GLORIA)

Toshio Matsumoto, Kazuhiko Yamamoto, Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Tetsuo Nakano, Masako Ito, Tatsushi Tomomitsu, Akihiro Hirakawa, Satoshi Soen

JOURNAL OF BONE AND MINERAL METABOLISM (2020)

Article Endocrinology & Metabolism

Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR

Seiji Fukumoto, Satoshi Soen, Tetsuya Taguchi, Takashi Ishikawa, Hisashi Matsushima, Masakazu Terauchi, Shigeo Horie, Toshiyuki Yoneda, Toshitsugu Sugimoto, Toshio Matsumoto

JOURNAL OF BONE AND MINERAL METABOLISM (2020)

Article Rheumatology

Predictors of new bone erosion in rheumatoid arthritis patients receiving conventional synthetic disease-modifying antirheumatic drugs: Analysis of data from the DRIVE and DESIRABLE studies

Tsutomu Takeuchi, Satoshi Soen, Naoki Ishiguro, Hisashi Yamanaka, Sakae Tanaka, Makiko Kobayashi, Naoki Okubo, Takaya Nitta, Yoshiya Tanaka

Summary: New bone erosion predictors in rheumatoid arthritis patients treated with conventional synthetic disease-modifying antirheumatic drugs include seropositivity, elevated inflammatory markers, and baseline erosion score greater than or equal to 3.

MODERN RHEUMATOLOGY (2021)

Article Medicine, General & Internal

Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS)

Satoshi Soen, Saeko Fujiwara, Ryoichi Takayanagi, Kenta Kajimoto, Mika Tsujimoto, Shuichi Kimura, Masayo Sato, John H. Krege, Hiroyuki Enomoto

CURRENT MEDICAL RESEARCH AND OPINION (2017)

No Data Available